|Professor Ian Frazer, FAA|
|Ian Frazer, trained as a renal physician in Edinburgh, Scotland, emigrated to Australia in 1981. After 4 years at the Walter and Eliza Hall institute, he moved to the University of Queensland where he is director of the University of Queensland Diamantina Institute, a translational medical research institute. He is currently the inaugural holder of the Queensland government Smart State Premier's fellowship, and past president of the Cancer Council Australia. |
Dr Frazer's laboratory research is focused on development of immunotherapeutic vaccines for virus associated cancers. In 1990, he and his then postdoctoral scientist, Dr Jian Zhou, developed technology for producing human papillomavirus virus like particles, the basis of vaccines recently brought to market to prevent cervical cancer. Dr Frazer is also developing vaccine delivery programs for these vaccines in Vanuatu and Nepal. In 2006 he was named Australian of the Year.
|Felix Herth is Chief Physician at the Thoraxklinik, Heidelberg University, Germany. He has been at the forefront of many of the development in interventional pulmonology and has published widely in the areas of TBNA, EBUS, Electromagnetic Navigation and airway stenting. The Thoraxklinik acts as a referral centre throughout Europe for many of these procedures.|
|Daniel H. Sterman|
|Daniel H. Sterman is Chief, Section of Interventional Pulmonology and Thoracic Oncology, Division of Pulmonary, Allergy & Critical Care Medicine, University of Pennsylvania Medical Center and Associate Professor of Medicine in Surgery, Department of Surgery, University of Pennsylvania School of Medicine. He was President, International Mesothelioma Interest Group (IMIG) 2004-06 and Secretary-Treasurer, President-Elect American Association of Bronchology and Interventional Pulmonology 2008-10. He has particular interests in interventional therapies for pulmonary malignant disease, particularly malignant mesothelioma, including the use of gene transfer therapies.|
|Professor Harm Tiddens|
|Harm Tiddens is Professor and pediatric pulmonary specialist at Erasmus MC Sophia Children's Hospital, Netherlands. The Erasmus CF centre is the 2nd largest CF centre in the Netherlands and participates in the European Clinical Trial Network that was established in 2008. He has a particular interest in monitoring of chronic lung diseases such as cystic fibrosis through the use of novel imaging and physiology techniques.|